Long-term cholinesterase inhibitor therapy for Alzheimer's disease: Implications for long-term care

American Journal of Alzheimer's Disease and other Dementias

Volumn 18, Issue 2, 2003, Pages 79-84

  Brangman, Sharon A ^a  

^a State University of New York Upstate Medical University: College of Medicine   (United States)

Author keywords

Alzheimer's disease; Cholinesterase inhibitors; Dementia; Donepezil

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; RIVASTIGMINE;

ALZHEIMER DISEASE; COGNITIVE DEFECT; DAILY LIFE ACTIVITY; DISEASE SEVERITY; DRUG EFFICACY; HUMAN; LONG TERM CARE; REVIEW; TREATMENT OUTCOME;

EID: 0037358815     PISSN: 15333175     EISSN: None     Source Type: Journal    
DOI: 10.1177/153331750301800204     Document Type: Review

References (37)

1. Galasko D: An integrated approach to the management of Alzheimer's disease: assessing cognition, function and behaviour. Eur J Neurol. 1998; 5 (suppl 4): S9-S17.
2. Francis PT, Palmer AM, Snape M, Wilcock GK: The cholinergic hypothesis of Alzheimer's disease: a review of progress. J Neurol Neurosurg Psychiatry. 1999; 66: 137-147.
3. Katzman R, Fox PJ: The world-wide impact of dementia: projections of prevalence and costs. In: Mayeux R, Christen Y, eds. Epidemiology of Alzheimer's disease: from gene to prevention. Heidelberg: Springer-Verlag; 1999: 1-17.
4. Evans DA, Funkenstein HH, Albert MS, et al: Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported. JAMA. 1989; 262: 2551-2556.
5. Krauss N, Altman B: Research findings no. 5: Characteristics of nursing home residents - 1996. Agency for Healthcare Research and Quality. Available at: http://www.meps.ahrq.gov/papers/rf5_99-0006/rf5.htm. Accessed May 29, 2001.
6. Magaziner J, German P, Zimmerman SI, et al: The prevalence of dementia in a statewide sample of new nursing home admissions aged 65 and older: diagnosis by expert panel. Epidemiology of Dementia in Nursing Homes Research Group. Gerontologist. 2000; 40(6): 663-672.
7. Kleinman L, Schmier J, Rothman M, et al: Time and costs of managing specific disruptive behaviors in long-term care facilities: A descriptive study. Consult Pharm. 2002; 17: 497-507.
8. Rice DP, Fillit HM, Max W, et al: Prevalence, costs, and treatment of Alzheimer's disease and related dementia: a managed care perspective. Am J Manag Care. 2001; 7(8): 809-818.
9. Hill J, Futterman R, Duttagupta S, et al: Alzheimer's disease and related dementias increase costs of comorbidities in managedmedicare. Neurology. 2002; 58: 62-70.
10. Gutterman E, Markowitz J, Lewis B, Fillit H: Cost of Alzheimer's disease and related dementia in managed-medicare. J Am Geriatr Soc. 1999; 47: 1065-1071.
11. Doody RS, Stevens JC, Beck C, et al: Practice parameter: management of dementia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001; 56: 1154-1166.
12. Rich JB, Rasmusson DX, Folstein MF, et al: Nonsteroidal anti-inflammatory drugs in Alzheimer's disease. Neurology. 1995; 45(1): 51-55.
13. Sano M, Ernesto C, Thomas RG, et al: A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med. 1997; 336: 1216-1222.
14. Le Bars PL, Kieser M, Itil KZ: A 26-week analysis of a double-blind, placebo-controlled trial of the ginkgo biloba extract EGb 761R in dementia. Dement Geriatr Cogn Disord. 2000; 11: 230-237.
15. Mulnard RA, Cotman CW, Kawas C, et al: Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: A randomized controlled trial. Alzheimer's Disease Cooperative Study. JAMA. 2000; 283(8): 1007-1015.
16. Farlow M, Gracon S, Hershey L, et al: A controlled trial of tacrine in Alzheimer's disease. The Tacrine Study Group. JAMA. 1992; 268(18): 2523-2529.
17. Knapp M, Knopman D, Solomon P, et al: A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA. 1994; 271(13): 985-991.
18. Rogers SL, Farlow MR, Doody RS, et al: A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology. 1998; 50(1): 136-145.
19. Burns A, Rossor M, Hecker J, et al: The effects of donepezil in Alzheimer's disease - results from a multinational trial. Dement Geriatr Cogn Disord. 1999; 10(3): 237-244.
20. Tariot P, Cummings J, Katz I, et al: A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. J Am Geriatr Soc. 2001; 49: 1590-1599.
21. Feldman H, Gauthier S, Hecker J, et al: A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology. 2001; 57: 613-620.
22. Tariot PN, Solomon PR, Morris JC, et al: A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology. 2000; 54(12): 2269-2276.
23. Wilcock GK, Lilienfeld S, Gaens E: Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group. BMJ. 2000; 321(7274): 1445-1449.
24. Corey-Bloom J, Anand R, Veach J: A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int J Ger Psychopharmacol. 1998; 1: 55-65.
25. Rosler M, Anand R, Cicin-Sain A, et al: Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ. 1999; 318(7184): 633-638.
26. Winblad B, Engedal K, Soininen H, et al: A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology. 2001; 57: 489-495.
27. Farlow M, Anand R, Messina JJ, et al: A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease. Eur Neurol. 2000; 44(4): 236-241.
28. Raskind MA, Peskind ER, Wessel T, Yuan W: Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology. 2000; 54(12): 2261-2268.
29. Doody RS, Geldmacher DS, Gordon B, et al: Open-label, multicenter, Phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer's disease. Arch Neurol. 2001; 58: 427-433.
30. Rogers SL, Doody RS, Pratt RD, Ieni JR: Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: Final analysis of a US multicentre open-label study. Eur Neuropsychopharmacol. 2000; 10: 195-203.
31. Mohs RC, Doody RS, Morris JC, et al: A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology. 2001; 57: 481-488.
32. Rogers S, Friedhoff L: The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial. The Donepezil Study Group. Dementia. 1996; 7(6): 293-303.
33. Rogers SL, Doody RS, Mohs RC, Friedhoff LT: Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Arch Intern Med. 1998; 158(9): 1021-1031.
34. Farlow M, Hake A, Messina J, et al: Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression. Arch Neurol. 2001; 58(3): 417-422.
35. Berg L, Miller J, Baty J, et al: Mild senile dementia of the Alzheimer type: 4. Evaluations of intervention. Ann Neurol. 1992; 31: 242-249.
36. Feldman H, Gauthier S, Hecker J, et al.: Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease, and the impact on caregiver burden. J Am Geriatr Soc. (In press).
37. White H, Pieper C, Schmader K: The association of weight change in Alzheimer's disease with severity of disease and mortality: a longitudinal analysis. J Am Geriatr Soc. 1998; 46(10): 1223-1227.